Curated News
By: NewsRamp Editorial Staff
May 19, 2025
Silo Pharma Closes $2M Public Offering to Advance Novel Therapeutics
TLDR
- Silo Pharma closed a $2 million public offering, providing potential investors with an opportunity for significant returns.
- Silo Pharma's public offering included 3,333,338 shares of common stock or pre-funded warrants at $0.60 per share, with proceeds allocated for general working capital.
- Silo Pharma's focus on developing novel therapeutics aims to address stress-induced psychiatric disorders, chronic pain conditions, and CNS diseases, potentially improving the quality of life for many individuals.
- Silo Pharma's lead program, SPC-15, offers an intranasal treatment for PTSD and stress-induced anxiety disorders, showcasing innovative approaches in biopharmaceutical research.
Impact - Why it Matters
This news matters as it highlights Silo Pharma's efforts to develop innovative treatments for underserved conditions. The successful public offering will provide the company with the necessary funds to further their research and development, potentially leading to groundbreaking therapies for psychiatric disorders, chronic pain, and CNS diseases.
Summary
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, closed a public offering of approximately $2 million in gross proceeds. The offering included common stock, pre-funded warrants, and Series A-1 and A-2 warrants, with H.C. Wainwright & Co. as the exclusive placement agent. The funds will be used for general working capital.
Silo Pharma focuses on developing novel therapeutics for stress-induced psychiatric disorders, chronic pain conditions, and CNS diseases. Their lead program, SPC-15, aims to treat PTSD and stress-induced anxiety disorders, while SP-26 is a time-release implant for fibromyalgia. Collaborations with universities and labs drive their research and development efforts.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Silo Pharma Closes $2M Public Offering to Advance Novel Therapeutics
